Arthur C. Butcher Sells 17,313 Shares of Boston Scientific Co. (NYSE:BSX) Stock

Boston Scientific Co. (NYSE:BSX) EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $101.80, for a total value of $1,762,463.40. Following the transaction, the executive vice president now owns 5,502 shares in the company, valued at approximately $560,103.60. This represents a 75.88 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Boston Scientific Trading Up 1.4 %

NYSE:BSX opened at $104.95 on Thursday. Boston Scientific Co. has a 12-month low of $64.08 and a 12-month high of $107.17. The firm has a market cap of $154.68 billion, a PE ratio of 86.73, a price-to-earnings-growth ratio of 2.68 and a beta of 0.80. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The stock has a fifty day moving average price of $94.01 and a 200 day moving average price of $86.71.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. Sell-side analysts anticipate that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on BSX shares. Mizuho lifted their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Thursday, October 24th. Royal Bank of Canada lifted their price target on shares of Boston Scientific from $95.00 to $98.00 and gave the company an “outperform” rating in a research report on Thursday, October 24th. Morgan Stanley increased their price objective on Boston Scientific from $92.00 to $100.00 and gave the stock an “overweight” rating in a research report on Thursday, October 24th. Piper Sandler lifted their target price on Boston Scientific from $95.00 to $115.00 and gave the company an “overweight” rating in a research report on Monday. Finally, StockNews.com upgraded Boston Scientific from a “hold” rating to a “buy” rating in a report on Wednesday, January 29th. One research analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $100.39.

Hedge Funds Weigh In On Boston Scientific

Several hedge funds have recently added to or reduced their stakes in BSX. Quarry LP purchased a new position in shares of Boston Scientific in the 2nd quarter valued at $33,000. Czech National Bank increased its position in shares of Boston Scientific by 7.1% during the third quarter. Czech National Bank now owns 299,989 shares of the medical equipment provider’s stock worth $25,139,000 after purchasing an additional 19,833 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Boston Scientific by 39.9% in the 3rd quarter. GAMMA Investing LLC now owns 17,432 shares of the medical equipment provider’s stock valued at $1,461,000 after purchasing an additional 4,972 shares during the last quarter. Miracle Mile Advisors LLC boosted its position in shares of Boston Scientific by 4.0% in the 3rd quarter. Miracle Mile Advisors LLC now owns 5,252 shares of the medical equipment provider’s stock valued at $440,000 after purchasing an additional 203 shares during the period. Finally, Bank of New Hampshire grew its stake in Boston Scientific by 52.6% during the 3rd quarter. Bank of New Hampshire now owns 2,235 shares of the medical equipment provider’s stock worth $187,000 after buying an additional 770 shares during the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.